IMC
Director Trades
| Date | Director | Value |
|---|
Company News
Market wrap: big banks send ASX into record territory
Australia’s big banks have pushed the ASX 200 to a record close of 7847 points after more signs of lower inflation in major economies caused a global relief rally. With interest rates now looking almost a certainty to fall in the big markets of the US, Europe and Australia, investors celebrated hard with a fresh […]
Immuron’s Travelan study results show major leap in digestive health protection, plans Phase 3 trial
Australian biopharmaceutical company Immuron (ASX: IMC) has released interim topline results from a US-based clinical trial of lead candidate IMM-124E (Travelan) confirming that a single daily dose can be effective in the prevention of moderate-to-severe diarrhea caused by enterotoxigenic Escherichia coli (ETEC). The double-blind, phase 2 controlled human infection model trial aimed to evaluate a […]
Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19. IMM-124E is used in Immuron’s over-the-counter Travelan and Protectyn products which were developed as immunotherapeutics to prevent travellers’ diarrhea and other gastrointestinal and digestive issues. The products are commercially available, with […]
Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli
Dual-listed biopharmaceutical company Immuron (ASX: IMC) is on course to make progress with a new oral therapeutic to treat campylobacteriosis and E. coli infections after development partner Naval Medical Research Center (NMRC) requested a pre-IND meeting with the US Food and Drug administration (FDA). Immuron and the NMRC could potentially see developmental progress made, despite […]
Immuron posts strong global sales growth for Travelan anti-diarrhoea product
Microbiome company Immuron (ASX: IMC) has posted a six-monthly unaudited gross revenue of $1.68 million for worldwide sales of its over-the-counter gastrointestinal and digestive health supplement Travelan. The company recorded robust gross sales growth in the US, Canada and Australia throughout the first half of the 2020 financial year, with revenue jumping 98% on the […]
US Department of Defense to fund Immuron in combatting gastrointestinal infections
Microbiome company Immuron (ASX: IMC), a firm that specialises in developing oral immunotherapeutic treatments for gut mediated diseases, has struck a $5.5 million deal with the US Department of Defense to engineer an effective therapeutic for traveller’s diarrhoea. More specifically, the US-based Naval Medical Research Center (NMRC) will fund the newly created research agreement with […]
Immuron’s Travelan anti-diarrhea product drives record revenue in North America
Immuron (ASX: IMC) revealed its full year 2019 revenue in North America has grown more than 50% to reach $1.16 million – driven by its Travelan gastrointestinal and digestive prophylactic health supplement to prevent traveller’s diarrhea. In the US, revenue from Travelan sales exceeded $1 million for the first time, with the product’s sales increasing […]
Immuron reports positive results from Travelan testing, develops anti-dysentery vaccine products
Australian biopharmaceutical company Immuron (ASX: IMC) has reported positive results from a study designed to test the efficacy of Travelan anti-dysentery medication on non-human primates. The placebo-controlled Shigellosis challenge study was conducted by the US Armed Forces Research Institute of Medical Sciences under a co-operative research and development agreement which Immuron has in place with […]
Immuron takes aim at the rapid growth of autoimmune diseases
Biopharmaceutical company Immuron (ASX: IMC) has hailed its colitis preclinical program at the University of Zürich, Switzerland as a complete success. Immuron is currently developing commercially viable “polyclonal antibodies” in oral form, for the treatment of inflammatory-mediated and infectious diseases such colitis i.e. inflammation of the colon as well as other diseases such as non-alcoholic […]
Immuron achieves strong sales numbers with Travelan
Microbiome biopharmaceutical company Immuron (ASX: IMC) has revealed encouraging sales numbers in relation to its over-the-counter gastrointestinal and digestive health supplement Travelan. The biotech company reported that the supplement continued its “robust sales growth” in the third quarter of the 2017-18 financial year, reaching A$1.37 million in revenue sales — a 40% increase on the […]